AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00123487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 140 mg QD, indefinitely, survival study
Study NCT00420849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
Study NCT03269474 — intervention group
Intervention type: PROCEDURE
Intervention: Experimental Group
Description: Subjects with EB diagnosis
Study NCT00420849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
Study NCT02486471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monsel´s Paste
Description: surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
Study NCT02486471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait and see
Description: finishing examination without hemostatic intervention, awaiting spontaneous coagulation
Study NCT02748213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
Study NCT05809960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing support program
Description: It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
Study NCT00538161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation strategy
Study NCT03782584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified pilates exercise
Description: modified exercises from original pilates exercises.
Study NCT00538161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation strategy
Study NCT03782584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: daily life advises
Description: they will be given daily life advises to prevent neck pain
Study NCT01699594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
Study NCT01699594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
Study NCT03178357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac rehabilitation + standard therapy
Description: Patients with HCM subjected to cardiological rehabilitation
Study NCT03178357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
Study NCT04517721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)
Description: The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
Study NCT04517721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)
Description: The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
Study NCT00925158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dissector Assisted Malar Elevation
Description: Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
Study NCT01981135 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study NCT01981135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study NCT01857544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Monthly 2.0mg Aflibercept Intravitreal Injection
Study NCT04121104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours
Study NCT04121104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is on
Study NCT01233817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Description: the systematic increase in resistance weights
Study NCT00905580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg orally
Study NCT00905580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Complex (placebo)
Description: Vitamin Complex 150 mg orally
Study NCT02872064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
Study NCT03678948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency-Based Debridement
Description: In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
Study NCT03678948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
Study NCT00135954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and steroids
Description: comparison of difference in time of start of therapy
Study NCT00135954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide and steroids
Description: comparison of difference in time of start of therapy
Study NCT04078282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: see above
Study NCT04078282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: see above
Study NCT01144312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
Study NCT03221582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR
Description: Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
Study NCT01787526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: 1 g intravenously per infusion
Study NCT01787526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral iron
Description: oral tablets of 100mg iron over 8 weeks, total dose 10g
Study NCT00475059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cimetidine arrow
Description: patients who received cimétidine
Study NCT03074422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
Study NCT03713762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peribulbar block 1 lidocaine/bupivacaine
Description: Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
Study NCT03713762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peribulbar block 2 lidocaine/bupivacaine/fentanyl
Description: Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
Study NCT03524326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 24 mg oral daily
Study NCT03524326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 20 mg oral daily
Study NCT03524326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 14 mg oral daily
Study NCT03524326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 IV, then 500mg/m2 IV weekly
Study NCT03524326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 10 mg oral daily
Study NCT03524326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: 4 mg oral daily
Study NCT01202773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously (SC)
Study NCT01202773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2127399
Description: Administered Subcutaneously (SC)
Study NCT01202773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Q4W
Description: Administered SC
Study NCT01354600 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise or Sedentary
Description: Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)
Study NCT01915381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multimodal intervention
Description: All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
Study NCT01915381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal intervention
Description: All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
Study NCT01370434 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: PAD combination
Description: * Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11
Study NCT03082820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain-related evoked potentials (PREP)
Description: PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
Study NCT03082820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing (QST)
Description: QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
Study NCT03082820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies (NCS)
Description: NCS were performed with patients only.
Study NCT00263796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 10 international units = 1 cc, IV over 4 hours
Study NCT00263796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline, IV over 4 hours
Study NCT00279799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Afiya HIV Prevention Intervention
Description: Group-based session plus individually tailored HIV prevention phone sessions
Study NCT01202773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Q2W
Description: Administered SC
Study NCT00279799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Afiya HIV prevention intervention
Description: Afiya group-based intervention + nutrition phone sessions (attention control)
Study NCT01711671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: 300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
Study NCT01711671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 600 mg
Description: 600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
Study NCT01711671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Current approved standard of care
Study NCT00924183 — intervention group
Intervention type: OTHER
Intervention: Treatment-as-usual
Study NCT01067859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 25 µg/h during 48 hours
Study NCT01067859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 10 µg/h during 48 hours
Study NCT01067859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of placebo during 48 hours
Study NCT01096706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NO clamp
Description: After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Study NCT01096706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Study NCT01096706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1.
Study NCT01096706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1.
Study NCT01096706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined
Description: Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms.
Study NCT03438305 — intervention group
Intervention type: OTHER
Intervention: sonar assessment of gastric volume in Diabetic patients
Description: assessment of gastric volume in Diabetic Patients
Study NCT05809960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin XR
Description: Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
Study NCT01557504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
Study NCT03438305 — intervention group
Intervention type: OTHER
Intervention: sonar assessment of gastric volume in Non Diabetic patients
Description: assessment of gastric volume in Non- Diabetic Patients
Study NCT04517981 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological intervention
Description: Choose according to the wishes of the enrolled subjects and the results of the evaluation
Study NCT04517981 — intervention group
Intervention type: OTHER
Intervention: Comprehensive intervention
Description: Choose according to the wishes of the enrolled subjects and the results of the evaluation